Takeda PharmaceuticalSee all their emails

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1

A real announcement email from Takeda Pharmaceutical. Captured July 23, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1 email from Takeda Pharmaceutical screenshot

Captured Announcement

Takeda announces the approval of ORZEYFUL in China as the first orexin agonist for Narcolepsy Type 1.

Top header with Takeda logo and tagline. Split hero banner with bold press release typography and laboratory image. Clean content section detailing the latest news release with a clear 'Learn More' link, followed by a feedback prompt and professional footer.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.